Super‐Selectivity versus Affinity‐Driven Targeting in Oncological Nanomedicine

Developing functional nanomaterials for targeted drug delivery remains a major goal of nanomedicine, particularly in oncology, where cytotoxic drugs often cause severe systemic toxicity. Most nanoparticle‐based strategies rely on surface ligands that bind receptors overexpressed on diseased cells. However, these receptors are rarely exclusive to tumors but frequently present in healthy tissues. As a result, decades of efforts to improve targeting by increasing ligand affinity have produced only limited clinical benefits. Affinity‐driven targeting generally leads to gradual, receptor density‐dependent binding, resulting in suboptimal biodistribution, off‐target accumulation, and dose‐limiting toxicity. Recent advances in nanomaterial engineering suggest an alternative paradigm inspired by viral infection. Rather than relying on high‐affinity interactions, viruses often exploit multivalent arrays of weak ligands to achieve highly selective cell recognition. Mimicking this strategy, synthetic nanoparticles can display spatially organized low‐affinity ligands whose cooperative interactions produce super‐selective binding, only above a critical receptor density. By tuning ligand valency, nanoscale geometry, and linker flexibility, these virus‐inspired nanostructures convert small differences in receptor abundance into sharp threshold‐like binding responses. Integrating multivalent recognition with rational nanomaterial design therefore offers a promising strategy to improve tissue discrimination and to achieve super‐selective, rather than merely targeted, drug delivery.